- Biohaven will receive up to $250 million to fund zavegepant’s development in migraine and non-migraine indications
- Royalty Pharma to acquire up to a 3% royalty for zavegepant, a 0.4% royalty of NurtecTM ODT and success-based milestone payments
- Royalty Pharma will purchase new Commercial Launch Preferred Equity from Biohaven for a total of $200 million payable between 2021 and 2024, providing additional funding for its CGRP-targeting franchise
Cooley acted as legal advisor to Biohaven on the transaction. Goodwin Procter, Jones Day and Maiwald acted as legal advisors to Royalty Pharma.
This text is a press release from Royalty Pharma.